Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Pharmaron Beijing Co., Ltd. Class H ( (HK:3759) ) has provided an update.
Pharmaron Beijing Co., Ltd. has proposed a final ordinary cash dividend of RMB 2 per 10 shares for the financial year ended 31 December 2025, with the Hong Kong dollar equivalent, key dates, and applicable withholding tax details to be announced. Subject to shareholder approval at the upcoming annual general meeting, the company expects to distribute the dividend by the end of August 2026, underscoring its commitment to returning capital to investors and signaling confidence in its financial performance.
The announcement also confirms that no warrants or convertible securities are associated with this dividend, simplifying the entitlement structure for shareholders. The company has appointed Tricor Investor Services Limited in Hong Kong to handle share registration matters, indicating a standard administrative process as the market awaits further details on record dates and payment logistics.
The most recent analyst rating on (HK:3759) stock is a Hold with a HK$21.50 price target. To see the full list of analyst forecasts on Pharmaron Beijing Co., Ltd. Class H stock, see the HK:3759 Stock Forecast page.
More about Pharmaron Beijing Co., Ltd. Class H
Pharmaron Beijing Co., Ltd. is a Hong Kong-listed pharmaceutical company operating in the life sciences sector. It focuses on providing drug research, development, and related services to global biopharmaceutical clients, leveraging its China base and international capital market presence to support long-term growth and shareholder returns.
YTD Price Performance: -5.41%
Average Trading Volume: 6,401,070
Technical Sentiment Signal: Sell
Current Market Cap: HK$50.1B
For detailed information about 3759 stock, go to TipRanks’ Stock Analysis page.